The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.

A flame-retardant compound, a process for forming a flame-retardant compound, and an article of manufacture. The flame-retardant compound includes a tetrazine moiety and at least one ligand comprising a brominated moiety. The process includes providing starting materials, which include a nitrile compound, a bromine source, and hydrazine. The process also includes reacting the starting materials to form a tetrazine flame retardant. The article of manufacture includes a polymer and a flame-retardant compound having a tetrazine moiety and at least one ligand comprising a brominated moiety.

A flame-retardant compound, a process for forming a flame-retardant compound, and an article of manufacture. The flame-retardant compound includes a tetrazine moiety and at least one ligand comprising a brominated moiety. The process includes providing starting materials, which include a nitrile compound, a bromine source, and hydrazine. The process also includes reacting the starting materials to form a tetrazine flame retardant. The article of manufacture includes a polymer and a flame-retardant compound having a tetrazine moiety and at least one ligand comprising a brominated moiety.

The present invention relates to novel tetrazine compounds of formula I, wherein one of R.sub.1-R.sub.5 is .sup.18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R.sub.1-R.sub.5 is SnR.sub.3, B(OR).sub.2, B(0H).sub.2. Formula (I).

##STR00001##

The present invention relates to novel tetrazine compounds of formula I, wherein one of R.sub.1-R.sub.5 is .sup.18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R.sub.1-R.sub.5 is SnR.sub.3, B(OR).sub.2, B(0H).sub.2. Formula (I).

##STR00001##

Disclosed herein are mono- and di-substituted tetrazines and methods of their preparation and converting an oxetanyl ester to a thio-substituted tetrazine, which is then converted to a mono-substituted tetrazine, a di-substituted tetrazine, or a vinylether disubstituted tetrazine.

Disclosed herein are mono- and di-substituted tetrazines and methods of their preparation and converting an oxetanyl ester to a thio-substituted tetrazine, which is then converted to a mono-substituted tetrazine, a di-substituted tetrazine, or a vinylether disubstituted tetrazine.

Bi-functional nanohybrids including a nanoparticle to the surface of which are covalently coupled chemical functions, one of which being biorthogonal, and their use as support for catalysts.

The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.

The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.